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Cytochrome P450 3A and ABC-transport Proteins in Horse 
Abstract 
In this thesis cytochrome P450 3A (CYP3A) and the ABC-transport proteins P-
glycoprotein (P-gp), breast cancer resistance protein (BCRP), multidrug resistance 
protein 1 (MRP1) and multidrug resistance protein 2 (MRP2) have been studied in 
horse.  
In the first part of the thesis the gene and protein expression, cellular localization 
and metabolic activity of CYP3A were investigated in the intestines, liver and upper 
respiratory airways. High levels of CYP3A gene and protein expression and 
metabolic activity were found in the small intestines. The CYP3A-related activity 
in the upper respiratory airways was high in spite of rather low levels of CYP3A 
gene and protein expression. A possible explanation in this observation is that there 
is an efficient electron transport from NADPH P450 reductase and cytochrome b5 
to CYP3A in these tissues. 
In the second part of the thesis gene and protein expression and cellular 
localization of P-gp, BCRP, MRP1 and MRP2 were studied in the intestines, liver 
and kidney. The expression and localization of the transporters in the tissues of 
horse showed both similarities and differences compared to other species. 
Collectively the results of the present thesis indicate that CYP3A and the 
examined ABC-transport proteins have important roles for bioavailability and 
elimination of substrate compounds in horse. 
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  8 Abbreviations  
ABC ATP-binding  cassette 
BCRP  breast cancer resistance protein 
DFB 3-(3,4-difluorobenzyloxy)-5,5-dimethyl-4-(4-
methylsulphonyl)-5H-furan-2-one 
CAR  constitutive androstane receptor 
Ct threshold  cycle 
CYP cytochrome  P450 
DFH 3-hydroxy-5,5-dimethyl-4-(4-methylsulphonyl)-5H-furan-2-
one 
DNA deoxyribonucleic  acid 
ECL enhanced  chemiluminescence 
GADPH glyceraldehyde-3-phosphatedehydrogenase 
HRP  horse radish peroxidase 
MDR1  multidrug resistance gene 1 
mRNA  messenger ribonucleic acid 
MRP  multidrug resistance protein 
MSD  membrane spanning domain 
NADPH  nicotine adenine dinucleotide phosphate, reduced form 
NBD  nucleotide binding domain 
P-gp permeability  glycoprotein 
PXR  pregnane X receptor 
PPAR  peroxisome proliferator-activated receptor 
RT-PCR  reverse transcription polymerase chain reaction 
RXR  retinoid X receptor 
SDS- 
PAGE 
sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis 
SNP  single nucleotide polymorphism 
SYBR green an asymmetrical cyanine dye used as nucleic stain 
TM transmembrane 
 
  9   10 1  Introduction 
 
Orally administrated drugs have to overcome several barriers before reaching 
the systemic circulation (Figure 1). Firstly the drugs are dissolved in the 
gastro-intestinal contents. Secondly they pass through the intestinal 
epithelium, where numerous efflux transporters are acting as barriers and 
thus prevent passage through the epithelium. Thirdly most drugs pass via the 
portal vein to the liver. Metabolism may take place both in the enterocytes 
and in the liver. Finally, the drugs or drug-metabolites are drained into the 
systemic circulation via the hepatic veins and the vena cava. Most drugs 
leave the body via the urine or bile, either non-metabolized or as polar 
metabolites. Several transport proteins are present in the nephrons of the 
kidney and may play important roles in the excretion of the drugs (Shitara et 
al., 2006). 
 
Figure 1. A schematic picture of the transfer of an orally administrated drug into the systemic 
circulation.  
  11 The metabolic pathway of a drug/xenobiotic can be divided into three 
phases: phase I-III. In phase I enzymes such as cytochrome P450 (CYP) 
enzymes introduce a functional group, usually an OH-group, into the 
substrate. Sometimes reactive metabolites, which may damage DNA or 
other cellular consituents, are formed at the phase I metabolism. In phase II 
transferase enzymes use the functional group as a handle for conjugation 
with endogenous constituents such as glucuronic acid, sulphate or 
glutathione to make the substrate hydrophilic. In phase III the conjugated 
substrate is pumped out of the cell by efflux transporters, such as multidrug 
resistance protein 1 (MRP1) and multidrug resistance protein 2 (MRP2) 
(Xu et al., 2005).  Other efflux transporters, such as P-glycoprotein (P-gp) 
and breast cancer resistance protein (BCRP), may prevent that the non-
metabolized drug/xenobiotic enters the cell by acting as efflux pumps at the 
cell membrane (Figure 2). 
 
Figure 2. A drug/xenobiotic that enters an enterocyte can directly be effluxed by transport 
proteins, such as P-gp or BCRP (1) or undergo phase I metabolism by a CYP-enzyme (2). 
Sometimes reactive metabolites are formed in the phase I metabolism, which may damage 
DNA or other cellular constituents (3). Normally, the phase I metabolite undergoes phase II 
metabolism (4) and is effluxed by a transport protein, such as MRP1 or MRP2 (phase III) (5).  
The liver is generally accepted to be the major organ involved in drug 
metabolism. In recent years the small intestine has also been shown to play 
an important role in the metabolism of orally administrated drugs (Kolars et 
al., 1994). In addition to the liver and the intestines, metabolizing enzymes 
  12 are present in extrahepatic tissues such as the mucosa of the upper airways 
(Ding and Kaminsky, 2003). 
 
Horses are treated with a variety of drugs, which may be substrates for the 
CYP-enzymes and the transport proteins. This also applies to some feed 
constituents as well as to xenobiotics present in the feed or in airborne 
particles in stables. The CYP enzymes and ABC-transporters have been 
extensively studied in man and laboratory animals, whereas little is known 
about these enzymes and efflux proteins in horse and other domestic 
animals. In this thesis investigations have been performed on the gene and 
protein expression, the cellular localization and the metabolic activity of the 
CYP3A in the intestines, liver and upper respiratory pathways in horse. In 
addition the gene and protein expression and the cellular localization of P-
gp, BCRP, MRP1 and MRP2 in the intestines, liver and kidney have been 
examined in horse.  
  13  
  14 2  The Cytochrome P450 Enzymes 
The cytochrome P450 super family (CYP) is an enzyme group critical for 
oxidation reactions in the phase I metabolism of xenobiotics. The name 
P450 was originally a description of a red pigment found in liver 
microsomes with an absorbance maximum at 450 nm in its reduced carbon-
monoxide form (Omura and Sato, 1964). The CYP enzymes are classified 
into families and subfamilies based on their amino acid sequence similarity.  
The enzymes are denoted CYP followed by a designation of family 
(number), subfamily (letter) and individual enzyme (number). To be 
members of the same family more than 40% of the amino acid sequence 
should be identical (e.g. CYP3) and to be members of the same subfamily 
55% of the amino acid sequence should be identical (e.g. CYP3A). Finally, 
each individual enzyme is represented by a number (e.g. CYP3A4). An 
updated list of CYP enzymes can be accessed at 
http://drnelson.utmem.edu/Cytochrome P450.htm    
 
The CYP enzymes can functionally be divided into two groups: those 
involved in endogenous metabolism, such as the biosynthesis of steroids, 
fatty acids and bile acid and those involved in xenobiotic metabolism. There 
are mainly three CYP families, CYP1, CYP2 and CYP3, involved in the 
xenobiotic metabolism (Zhang and Benet, 2001; Zuber et al., 2002). The 
CYP1 family includes among others, CYP1A, which is responsible for the 
metabolism of several environmental toxins, such as polycyclic aromatic 
hydrocarbons (Ding and Kaminsky, 2003). The CYP2 family is a large 
family with several subfamilies among which CYP2C, CYP2D and CYP2E 
are involved in the metabolism of several clinically relevant drugs (Ding and 
Kaminsky, 2003). The third family, CYP3A, is considered the primary CYP 
subfamily to be involved in drug metabolism (Zhang and Benet, 2001). 
 
  15 In mammals the CYP enzymes are mainly anchored at the cytosolic side of 
the endoplasmic reticulum, but there are also some CYP enzymes present in 
the inner membranes of mitochondria (Ding and Kaminsky, 2003; 
Gonzalez, 1988). The catalytic activity of the CYP enzymes is dependent on 
presence of electron-donating co-factors such as NADPH P450 reductase 
and cytochrome b5. Thus, transfer of an electron from NADPH P450 
reductase to CYP occurs during the metabolic CYP-cycle (Nakajima et al., 
2002; Schenkman and Jansson, 2003; Wu et al., 2005).  Moreover 
cytochrome b5 has been shown to promote the metabolic activity of the 
CYP-enzymes by facilitating the transfer of a second electron to the CYP-
cycle (Nakajima et al., 2002; Yamazaki et al., 1996). 
2.1  CYP3A 
CYP3A is an important CYP. In addition to the liver CYP3A is expressed 
in several extrahepatic tissues such as the nasal olfactory and respiratory 
mucosa, tracheal mucosa, lung and the mucosa of oesophagus and intestines 
(Ding and Kaminsky, 2003). In man the CYP3A subfamily has been 
reported to be responsible for approximately 60% of all oxidative drug 
metabolism (Wilkinson, 2005). This subfamily has been highly conserved in 
mammals. In man the most important isoenzyme within this subfamily is 
CY3A4 (Kolars et al., 1994). The horse orthologue to human CYP3A4 is 
designated CYP3A89. A comparison of the amino acid sequences of the 
horse CYP3A89 with the orthologous CYP3A4-enzymes in man, dog and 
rat is shown in Table 1.  
 
CYP3A4 was first identified by Watkins et al. (1985) and cloned the year 
after (Molowa et al., 1986). In 2004 the crystal structure of CYP3A4 was 
reported (Williams et al., 2004) and two years later it was shown that 
CYP3A4 undergoes dramatic conformational changes upon ligand binding, 
with an increase in the active-site volume of more than 80%. This may 
explain the broad substrate specificity of CYP3A4 (Ekroos and Sjögren, 
2006). (Watkins et al., 1985) 
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Table 1. Comparison of horse CYP3A89 with orthologous CYP3A4-enzymes in human, 
dog and rat.  
Species Name  Chromosome 
location
a 
Number of 
amino acids 
 
Identity 
with horse 
(%) 
Accession 
number
b 
 
Horse CYP3A89
  13 502  (100)  A7LGW7 
Human CYP3A4
  7 502  82  P08684 
Dog CYP3A12  6  503  84  P24463 
Rat CYP3A23/A1  12  504  67  P04800 
a chromosome location www.ensembl.org, 
b accession number from UniProt 
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  18 3  The ABC-transporter Family 
ATP-Binding Cassette (ABC) transport proteins comprise the largest 
superfamily of transport proteins. The ABC genes have been divided into 
seven subfamilies, designated A through G, based on the similarities of their 
amino acid sequences (Deeley et al., 2006; Klein et al., 1999). The members 
of the ABC family are ubiquitously present in various biological systems and 
are expressed in numerous organisms, ranging from bacteria to mammals. 
They are all involved in the trafficking of biological molecules across cell 
membranes (Borst et al., 2000; Higgins, 1992). The core functional unit of 
the ABC transporters consists of two polytrophic membrane-spanning 
domains (MSD) and two nucleotide-binding domains (NBD) (Figure 3). 
The MSD domains may vary between 5-10 transmembrane helices but 
usually consist of 6 transmembrane helices (Deeley et al., 2006).  The two 
NBD utilize the energy from ATP hydrolysis to transport the substrates 
through pores across the cellular membrane. The ATP-binding region is 
highly conserved and is one the characteristic for this superfamily. In 
eukaryotes all ABC-transporters are efflux proteins, whereas in prokaryotes 
they can be either efflux or influx proteins (Higgins, 2007). Some genetic 
disorders in humans, such as Tagnier disease, Stargardt disease, Dubin-
Johnson syndrome and cystic fibrosis are associated with dysfunctions of the 
ABC-transporters (Deeley et al., 2006; Keitel et al., 2003). 
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Figure 1. Schematic picture of the topology of human P-gp, MRP1 and MRP2, and BCRP 
in cellular membranes (Deeley et al., 2006; Mao and Unadkat, 2005). 
3.1  P-glycoprotein 
P-glycoprotein (P-gp), where “P” stands for permeability, encoded by the 
ABCB1 gene (also referred to as the MDR1 gene), was the first eukaryotic 
ABC transporter discovered (Juliano and Ling, 1976). P-gp was observed to 
cause a multidrug-resistant phenotype in Chinese hamster ovary tumour 
cells (Juliano and Ling, 1976). Since then a vast number of studies have been 
performed on the structure, mechanism of action and physiological and 
pharmacological roles of P-gp. A comparison of the amino acid sequences of 
horse P-gp with orthologues in human, dog and rat is shown in Table 2. It 
can be seen that horse P-gp has about 100 amino acids more than P-gp in 
the other species. It is considered that P-gp plays a role in the efflux 
transport of various endogenous compounds, such as cholesterol, cytokines 
and steroids (Leslie et al., 2005). P-gp is also responsible for the transport of 
a variety of exogenous compounds including several drugs (Seelig, 1998). 
  20  
P-gp is expressed in various tissues such as the intestine, liver, kidney, brain 
and placenta. The localisation of P-gp suggests a functional role in the 
protection against negative effects of xenobiotics by facilitating excretion of 
the compounds into the intestinal lumen, the bile and the urine and by 
preventing the uptake into the brain and the fetus. In the intestines P-gp is 
expressed in the apical membrane of the enterocytes in which it may limit 
the bioavailability of orally administrated drugs (Thiebaut et al., 1987). In 
the liver P-gp is present in the biliary canalicular membranes of the 
hepatocytes and may promote secretion of drugs into the bile (Schinkel and 
Jonker, 2003). In the kidney P-gp is primarily localized at the luminal 
surfaces of the cells of the proximal tubules and may play a role in the 
elimination of drugs and other xenobiotics from blood into urine (Thiebaut 
et al., 1987).  
Table 2. Comparison of horse P-gp with orthologues in human, dog and rat 
Species Names  Chromosome 
location
a 
Number of 
amino acids
b  
 
Identity % 
 
Accession 
number
b 
Horse ABCB1  4  1382  (100)  XP001492073 
Human ABCB1  7  1280  90  P08183 
Dog ABCB1  14  1283  92  O46605 
Rat ABCB1a 
ABCB1b 
4 
4 
1272 
1277 
85 
78 
QPPSM0 
P43245 
a chromosome location www.ensembl.org, 
b UniProt,
  
 
 
So far, rodents are the only species known to have two P-gp. These are 
encoded by the genes Mdr1a (ABCB1a) and Mdr1b (ABCB1b). The tissue 
distribution of Mdr1a and Mdr1b differ from each other but collectively the 
two isoforms have the same distribution in the body as human P-gp (Leslie 
et al., 2005). Collies and dogs of collie-related breeds sometimes carry a 
single nucleotide polymorphism (SNP) within the ABCB1, which results in 
a defect function of the P-gp protein. When these dogs are treated with 
ivermectin, which is a P-gp substrate, neurotoxic effect may occur due to 
passage of the substance over the blood-brain barrier (Mealey, 2004). 
 
  21 3.2  Breast Cancer Resistance Protein 
Breast cancer resistant protein (BCRP), encoded by the ABCG2 gene, was 
cloned from a doxorubicin-resistant breast cancer cell line in 1998 and is 
one of the latest discovered members of the ABC-transporter family (Doyle 
et al., 1998). BCRP is a “half transporter” consisting of only one set of 6 
TM helices and one NBD. A homodimerisation is needed for BCRP to 
become a functional unit (Klein et al., 1999). BCRP is located in the plasma 
membrane whereas other “half transporters” often are located intracellularly 
(Mao and Unadkat, 2005). BCRP transports a variety of exogenous 
unconjugated and conjugated compounds (Mao and Unadkat, 2005; Vander 
Borght et al., 2006).  
 
It has been suggested that BCRP has similar functions as P-gp and that they 
may act together as tissue-barrier, protecting the body against toxic 
xenobiotics. The substrate specificity of BCRP partly overlaps those of P-gp 
and the MRPs and it has become clear that BCRP is one of the major ABC 
transporters affecting drug disposition (Haimeur et al., 2004; Mao and 
Unadkat, 2005). 
 
In humans BCRP is expressed in various organs, such as the intestines, liver, 
kidney, placenta, brain and mammary gland (Maliepaard et al., 2001). A 
comparison of the amino acid sequences of horse BCRP with orthologues 
in human, dog and rat is shown in Table 3. There are several known 
species-differences in the tissue distribution of BCRP. For example is 
BCRP located in the biliary canalicular membranes of hepatocytes in human 
liver but not in rat liver (Vander Borght et al., 2006). 
Table 3. Comparison of horse BCRP with orthologues in human, dog and rat  
Species Name  Chromosome 
location
a 
 
Number of 
amino acids
b 
Identity % 
 
Accession 
number
b 
Horse ABCG2  3  654  (100)  XP0011496382 
Human ABCG2  4  655  86  Q9UN0 
Dog ABCG2 32  654  86  Q38JL0 
Rat ABCG2 4  656  82  Q800W57 
a chromosome location www.ensembl.org, 
b UniProt 
 
  22 3.3  The Multidrug Resistance Protein Family 
The multidrug resistance protein subfamily (MRP, ABCC) comprises 13 
members, where MRP1, 2, 3, 4, 5, 6 and 8 are known to be involved in 
transport of drugs (Schinkel and Jonker, 2003). The structure of the 
members of the ABCC subfamily is related to most other ABC- 
transporters. They contain two MSD, each followed by a nucleotide binding 
domain. However, MRP1 and MRP2 belong to the “long” MRPs having 
an additional MSD and an extracellular location of the N-terminal. The 
additional transmembrane domain of MRP1 and MRP2 may be required 
for proper function but the detailed role of this additional MSD is not yet 
known (Deeley et al., 2006). 
3.3.1  MRP1 
MRP1 (ABCC1) was the first member in the ABCC subfamily to be cloned 
in 1992 from a drug-selected human lung cancer cell line (Cole et al., 1992). 
MRP1 has been reported to be located at the plasma membrane on the 
basolateral side of polarized cells. In human MRP1 is expressed in several 
tissues (Bakos and Homolya, 2007). MRP1 orthologues show high sequence 
identity with one another but have some remarkable differences in the 
substrate specificity. A comparison of the amino acid sequence of MRP1 in 
horse with orthologues in human, dog and rat is shown in Table 4. 
 
The wide substrate specificity and widespread expression of MRP1 suggests 
numerous possible physiological functions, which still have to be explored. 
MRP1 transports phase II conjugates as well as some non-conjugated 
compounds (Deeley and Cole, 2006). MRP1 is a transporter of cystein 
leukotriene C4 (LTC4) and thus plays a role in inflammatory response (Leslie 
et al., 2005). In severe liver disease MRP1 is up- regulated in the 
hepatocytes (Ros et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
  23 Table 4. Comparison of horse MRP1 with orthologues in human, dog and rat  
Species Name Chromosome 
location
a 
 
Number of 
amino acids
b 
Identity % 
 
Accession 
number
b 
Horse ABCC1  13  1531  (100)  Q0NXS 
Human ABCC1  16  1531  89  P33527 
Dog ABCC1  6  1531  90  Q6UR05 
Rat ABCC1  10  1532  85  Q8CG09 
a chromosome location www.ensembl.org, 
b UniProt,  
 
3.3.2  MRP2 
Multidrug resistance protein 2 (MRP2, ABCC2) was the second member of 
in this subfamily to be cloned in 1996 from normal rat liver (Paulusma et al., 
1996). MRP2 is also referred to as multispecific organic anion transporter 
(cMOAT). MRP2 is expressed in the bile canalicular membranes of 
hepatocytes, in the brushborder membranes of enterocytes and in the renal 
proximal tubules. This localization indicates a role of MRP2 in excretion of 
xenobiotics. Lower levels of MRP2 are found in lung, stomach and placenta 
and there are contradictory reports concerning the expression of MRP2 in 
the blood-brain barrier (Fardel et al., 2005). The substrate specificity of 
MRP2 is broad, and is to some extent overlapping with that of MRP1 
(Keppler et al., 2000). The substrates of MRP2 include glucuronic acid and 
GSH conjugates of substances. MRP2 is considered to play an important 
role in the elimination of conjugates of various xenobiotics from intestinal 
epithelial cells into the intestinal lumen, from hepatocytes into the bile and 
from kidney proximal tubules into the urine (Keppler et al., 2000; Keppler 
and Köng, 1997; Nies and Keppler, 2007). Moreover, MRP2 plays an 
important role in the hepatic excretion of bilirubin. It has been shown that a 
dysfunction of MRP2 in the liver in man results in hyperbilirubinemia and 
may cause Dubin-Johnson syndrome (Keitel et al., 2003). A comparison of 
the amino acid sequence of MRP2 in horse with orthologues in human, dog 
and rat is shown in Table 5. 
 
 
 
 
 
 
 
  24 Table 5. Comparison of horse MRP2 with orthologues in human, dog and rat 
Species Name Chromosome 
location
a 
Number of 
amino acids
b 
Identity % 
 
 
Accession 
number
b 
Horse ABCC2  1  1544  (100)  XP001500757.1 
Human ABCC2  10  1545  82  Q92887 
Dog ABCC2  28  1544  85  Q6PSM3 
Rat ABCC2  1  1541  77  Q63120 
a chromosome location www.ensembl.org, 
b UniProt,  
  25  
  26 4  Gene Regulation of CYP enzymes and 
ABC transporters  
Many xenobiotics have been shown to directly or indirectly regulate the 
expression of the CYP enzymes as well as the expression of the ABC 
transporters via the nuclear receptor pathways. The orphan pregnane X 
receptor (PXR), is one of the key regulators for the expression of P-gp, 
MRP2 and CYP3A (Wilkinson, 2005). Thus, in response to activation of a 
ligand PXR forms a heterodimer with the retinoid X receptor (RXR). The 
PXR-RXR heterodimer then binds to the promoter regions of P-gp, 
MRP2 or CYP3A, thereby increasing transcription (Goodwin et al., 2002). 
The intestinal and the hepatic expression of CYP3A are highly dependent 
on the activity of PXR (Urquhart et al., 2007). For example the PXR 
ligand rifampicin has been shown to reduce the plasma concentrations of 
some orally co-administrated drugs by induction of intestinal P-gp. Another 
example is the PXR ligand hyperforin (present St. John´s wort), which 
induces both P-gp and CYP3A and thus may reduce the oral bioavailability 
of some drugs (Synold et al., 2001). An illustration of how drug interactions 
may occur as a result of effects on nuclear receptor pathways is shown in 
Figure 4. 
  27  
 
Figure 4. Illustration of the molecular mechanism of a drug interaction via interferance in a 
nuclear receptor pathway. The PXR receptor is a transcription factor that regulates the 
expression of the CYP gene e.g. in the liver and intestine. It functions as a heterodimer 
together with the nuclear receptor RXR. Drug A binds to PXR and induces expression of 
the CYP enzyme, which in turn stimulates the metabolism of drug B that is a substrate for 
CYP (Willson and Kliewer, 2002). 
 
Another nuclear receptor is the constitutive androstane receptor (CAR). 
CAR also forms a heterodimer with RXR, thus increasing the expression of 
CYP3A, P-gp and MRP2. There is an overlap in the substrate specificity of 
CAR and PXR (Kliewer et al., 2002; Willson and Kliewer, 2002). 
 
The mechanism of the regulation of BCRP is not yet fully understood, but 
it appears that the regulation of BCRP-expression does not involve 
regulation by PXR or CAR (Choudhuri and Klaassen, 2006). Recently the 
nuclear receptor peroxisome proliferator-activated receptor gamma 
(PPARγ) has been shown to be responsible for the regulation of BCRP. 
PPARγ also forms a heterodimer with RXR, in this way increasing the 
expression of BCRP (Urquhart et al., 2007). 
 
MRP1 is not regulated via the nuclear receptor pathway. Instead it is 
suggested that MRP1 is regulated by muliple regulatory mechanisms. 
Among others have the transcriptional factors of the antioxidant responsive 
element driven genes been found to be involved in the expression of MRP1 
(Bakos and Homolya, 2007). 
  28 5  CYP enzymes and Transport Proteins in 
Horse 
Little is known regarding CYP enzymes and ABC-transport proteins in 
horse. Concerning the CYP enzymes the few reports that are available have 
dealt with the metabolic capacity and protein expression of CYP in horse 
liver microsomes. CYP enzymes examined include CYP1A, CYP2B, 
CYP2E, CYP2D and CYP3A (Lakritz et al., 2000; Nebbia et al., 2004). 
Comparative studies on CYP dependent activities which include horses are 
few (Chauret et al., 1997; Nebbia et al., 2003).  
Table 6. Comparisons of metabolic activities of some CYP-enzymes in liver microsomes 
from human, horse and dog.  Data modified from Chauret et al. (1997) (Chauret et al., 1997) 
Human CYP 
 
Substrates   Human  
(%)  
Horse  
(% of  human) 
Dog   
(% of  human)  
CYP1A1/2 Phenacetin-O-
deethylase 
(100) 39  145 
CYP2A6 Coumarin-7-
hydroxylase 
(100) 24  17 
CYP2C8/9 Tolbutamide 
hydroxylase 
(100) 170  18 
CYP2C19 S-methenytoin-4-
hydroxylase 
(100) 171  100 
CYP2D6 Dextrometorphan-
O-demethylase 
(100) 221  41 
CYP2E1 Chlorazoaxazone-
6-hydroxylase 
(100) 208  122 
CYP3A4 Testosterone-6β-
hydroxylase 
(100) 14  14 
(Chauret et al., 1997) 
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horse and dog were incubated with substrates reported to be selective for 
particular CYP enzymes. It appears that there exist rather large differences in 
the metabolic CYP-related activities between these species.  
 
Recently the first clone of a horse CYP, namely CYP2D50, was reported 
(DiMaio Knych and Stanley, 2008). The nucleotide sequence was highly 
homologous to human CYP2D6. Interestingly, there were striking 
differences in the dextromethorphan-O-demethylase activity between horse 
and human. Thus, horse CYP2D50 had a much lower capacity to 
metabolize dextromethorphan-O-demethylase than human CYP2D6 
(DiMaio Knych and Stanley, 2008). This is in contrast to the report by 
Chauret et al. (1997) where horse liver microsomes had twice as high 
metabolic capacity of dextromethorphan-O-demethylase compared to 
human liver microsomes (Table 6). These data suggest that additional CYP-
enzymes in horse liver microsomes can metabolize this substrate.  
 
Regarding phase II enzymes there are also species differences between horse 
and other mammals. For example have the levels of glutathione- and acetyl-
conjugations of various substrates shown marked differences in horse 
compared to other domestic animals (Gusson et al., 2006). 
 
Concerning the ABC-transport proteins there are no reports available on 
species differences between horse and other species. 
5.1  Drug interactions in horse 
When two or more drugs that are substrates for either CYP enzymes or 
transport proteins are administrated together there is a potential possibility of 
drug interactions. Drug interactions can lead to inhibition or induction of 
the CYP enzymes or the transport proteins, resulting in increased or 
decreased tissue levels of one or both drugs. Compounds present in herbs 
and feed constituents or feed supplements may also inhibit or induce the 
CYP enzymes and the transport proteins. (Williams and Lamprecht, 2008) 
 
As concerns the horse little is known about drug-drug interactions or drug-
herb interactions. According to the review by Williams and Lamprecht 
(2008) there is an overall increase of the herbal supplements on the market 
and especially the market for horses. Various herbal supplements that are 
commercially available for horses may be substrates for the CYP enzymes or 
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cause drug-herb interactions (Table 7). 
Table 7. Compounds present in herb supplements that are commercially available for horses 
in Sweden and have been reported to inhibit or induce CYP3A and/or transport proteins 
Active plant 
component  
Herb 
CYP3A P-gp  BCRP  MRP1  MRP2 References 
Alkamides 
 Echinacea 
inhibit inhibit          3 
bergamottin 
Pea/clover/carrot 
inhibit  inhibit         1, 2 
gingerol  
Ginger 
induce induce          4 
ginsensosides 
Ginseng 
inhibit  inhibit  inhibit       1, 5, 6 
 
glabridin  
Liquorice root 
inhibit  inhibit         1, 2, 7 
 
glycosides  
Devils claw root 
inhibit           8 
quercetin  
Garlic 
inhibit  inhibit  inhibit    inhibit   1, 2, 9 
 
silymarin  
Milk thistle 
seed/Meadow 
sweet  
inhibit inhibit  inhibit      1,  10, 
 
1. (Zhou et al., 2004b), 2. (Zhou et al., 2004a), 3. (Hellum and Nilsen, 2008), 4. (Brandin et al., 2007), 
5. (Jin et al., 2006), 6. (Hao et al., 2008), 7. (Nabekura et al., 2008), 8. (Unger and Frank, 2004), 9. 
(Tanaka et al., 2005), 10. (Doehmer et al., 2008) 
 
 
Example of drugs used in equine therapy in Sweden that are substrates for 
CYP3A or transport proteins are given in Table 8. It can be noted that 
during the time period 2005-2006 there has been an increase of 8% of the 
sale volumes of equine drugs in Sweden (Grunberger, 2007). The most 
frequently prescribed drugs to horses are antibiotics and anti-inflammatory 
and anti-parasitic drugs.  
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substrates, inducers or inhibitors of CYP3A and/or transport proteins.  
Active component 
Drug 
CYP3A P-gp  BCRP  MRP1  MRP2  References 
ampicillin 
Ampivet® 
     substrate  1   
dexamethason 
Opticorten® 
Dexadreson® 
Vorenvet® 
induce induce induce/ 
inhibit 
  induce  2, 3, 4 
fenbendazole 
Axilur® 
inhibit       5   
ivermectin 
Bimectin® 
Equimax® 
Noromectin® 
Ivomec® 
Ivomec comp® 
substrate  substrate     substrate   substrate  6, 7, 8 
ketamin  
Ketalar® 
Ketaminol® 
substrate       9 
lidocaine  
Xylocain® 
substrate       10 
meloxicam 
Metacam® 
substrate       11 
moxidectin 
Cydectin® 
substrate substrate   substrate substrate 12,  13   
omeprazole 
Gastroguard® 
induce induce inhibit      14,  15 
phenylbutazone 
Fenylbutazon® 
induce         16   
praziquantel 
Cydectin comp® 
Equimax® 
Ivomec comp® 
substrate  inhibit        17, 18  
1. (Fardel et al., 2005), 2. (Pascussi et al., 2000), 3. (Honorat et al., 2008), 4. (Narang et al., 2008), 5. 
(Baliharova et al., 2004), 6. (Lespine et al., 2006), 7. (Brayden and Griffin, 2008), 8. (Zeng et al., 1998), 
9. Hijazi drug met disp 2002, 10. (Aiba et al., 2003), 11. (Chesne et al., 1998), 12. (Dupuy et al., 2006), 
13. (Dupuy et al., 2001), 14. (Mao and Unadkat, 2005), 15.  (Brandin et al., 2007), 16. (Ogg et al., 
1999), 17. (Li et al., 2003), 18. (Hayeshi et al., 2006) 
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Examined Tissues  
6.1  The alimentary canal 
Being a grazing animal horse will ingest large amounts of cellulose. It can be 
suitable to divide the alimentary canal in horse into two parts: an anterior 
part (the foregut) and a posterior part (the hindgut). The foregut consists of 
the mouth, pharynx, oesophagus, stomach, duodenum, jejunum and ileum. 
The hindgut consists of the caecum, colon and rectum. The physiology of 
the foregut is similar to that in omnivorous species such as human and pig. 
To digest the cellulose in the feed horses are dependent on the large number 
of fermentating microorganisms, which are present in caecum and colon. 
The hindgut of horse has thus a similar function as the rumen and the 
reticulum in ruminants (Copenhaver et al., 1978; Kararli, 1995; Sisson, 
1961). 
 
The cellulose-fermenting microorganisms may also metabolize some 
xenobiotics, such as mycotoxins. This implies that in ruminants, some 
xenobiotics will be metabolized in the rumen and the reticulum, thus prior 
to entering the absorptive epithelium in the small intestine. This may render 
ruminants less sensitive to the potentially negative effects of such compounds 
compared to horses, in which the metabolism will not take place until in the 
caecum and colon, thus after the passage through the small intestine. 
 
The structure of the small intestine provides a very large surface area (Figure 
5). Firstly, the inner intestinal wall contains numerous folds. Secondly, the 
intestinal surface epithelium has finger-like villi. Thirdly, the epithelial 
enterocytes have fine extensions called microvilli that create a brush border 
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lacks folding and villi and has a higher amount of mucous producing cells 
(goblet cells) than the small intestine (Copenhaver et al., 1978; Sisson, 
1961). 
 
Figure 5.  A schematic picture of the crypt-villous functional unit of the small intestine. The 
mucosal epithelium is rapidly renewing from proliferative cells, which are located at the 
bottom of the crypts. The localization of P-gp, BCRP, MRP1 and MRP2 in an enterocyte 
is also indicated (Choudhuri and Klaassen, 2006). Legends: LPL, lamina propria lymphocytes; 
IEL, intraepithelial lymphocytes 
The main cell-type in the intestinal epithelium is the single layered 
absorptive enterocyte, which is present at the surface epithelium and 
accounts for 80-90% of the total number of the epithelial cells. The 
enterocytes at the tip of the villi are functionally mature and non-dividing 
cells, whereas the crypt cells are immature and dividing. Mucous-producing 
goblet cells are interspersed among the absorptive enterocytes. Additional 
cell-types include endocrine cells and Paneth cells. The submucosa of the 
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in contrast to most other species, contain both mucous and serous acini 
(Pfeiffer and Dabareiner, 1992). 
 
The lamina propria is the tissue layer between the surface epithelium and the 
muscularis mucosa. It contains smooth muscle cells, lymphatic vessels, blood 
vessels and a considerable number of lymphocytes (lamina propria 
lymphocytes; LPL), macrophages and mast cells. Lymphocytes are also 
interspersed among the enterocytes of the surface epithelium (intraepithelial 
lymphocytes; IEL) (Ferguson, 1977). The IEL and LPL consist mainly of T-
cells. It has been estimated that in man there is a normal range of 10 to 30 
IEL per 100 epithelial enterocytes (Ferguson, 1977). The number of IEL in 
relation to the number of epithelial enterocytes in horse is not known.  
 
6.2  Liver 
The liver is the largest gland in the body. The liver is involved in processing 
and storage of all categories of food materials (fats, carbohydrates, proteins, 
vitamins), removal of waste products from the blood and the synthesis of 
serum proteins, lipoproteins and clotting factors. It is also the major site for 
metabolism of xenobiotics. Horses have no gallbladder but a bile duct system 
with a wide calibre. The hepatic lobule, which can be considered to be the 
anatomical unit structure of the liver, contains a system of anastomosing 
blood sinusoids (Figure 6). The parenchyma is arranged in irregular cords. 
The duct system of the liver serves to convey the bile to duodenum. The 
smallest branches of the duct system are the bile canaliculi, which form a 
ramifying network of channels between the parenchymal cells. The 
canaliculi drain into bile ducts in the periphery of the lobules (Copenhaver 
et al., 1978; Sisson, 1961). 
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Figure 6. A schematic picture of the architecture in the liver. The picture also shows the membrane 
localization of P-gp, BCRP, MRP1 and MRP2 in the hepatocyte. The localizations of the transporters 
in the hepatocytes show variations between species. CYP enzymes are mainly present in the endoplasmic 
reticulum in hepatocytes. Modified from www.assofade.org 
6.3  Kidney 
Functions of the kidney include the regulation of water, electrolytes and 
acid-base balance, regulation of the blood pressure, metabolism of 
endogenous and exogenous compounds and excretion of waste products and 
exogenous compounds. The morphologically the equine nephrons and the 
basic renal processes are similar to those of most other species (Figure 7) 
(Toribio, 2007).  
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Figure 7. A schematic picture of a nephron and a tubule. The picture also indicates 
membrane localizations of P-gp, BCRP, MRP1 and MRP2 in proximal tubule cells 
(Choudhuri and Klaassen, 2006). The membrane localizations of the transporters show 
variations between species. 
6.4  Tissues of the upper airways 
The nasal olfactory epithelium is composed of three cell types: olfactory 
neurons, sustentacular cells and basal cells (Figure 8A). The nasal respiratory 
epithelium is a pseudo-stratified columnar epithelium, which contains four 
cell types: ciliated cells, non-ciliated (mucous) cells, goblet cells and basal 
cells (Figure 8B and C). The epithelium of the trachea has a similar structure 
as the nasal respiratory epithelium. The nasal olfactory mucosa contains 
Bowman’s glands localized in the lamina propria. Beneath the nasal 
respiratory mucosa and the tracheal mucosa serous and mucous glands are 
present in the submucosa (Copenhaver et al., 1978). 
 
A potent CYP-related metabolism has been shown in the nasal olfactory and 
respiratory mucosa and the tracheal mucosa in several species, including the 
horse (Larsson et al., 1989; Larsson and Tjälve, 1996; Tydén et al., 2008). 
The CYP-containing cells in the nasal olfactory mucosa are the sustentacular 
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mucosa CYP-enzymes are present in the non-ciliated (mucous) cells 
(Grunberger, 2007; Larsson et al., 2003; Larsson et al., 1989). 
 
Figure 8. A schematic picture of the nasal olfactory mucosa (A), nasal respiratory mucosa (B) 
and tracheal mucosa (C). CYP-enzymes are present in the sustentacular cells and the cells of 
Bowman’s glands in the nasal olfactory mucosa and in the non-ciliated (mucous) cells in the 
nasal respiratory mucosa and the tracheal mucosa. Legends: B, basal cell; Bg, Bowman’s 
gland; G, goblet cell; N, olfactory neuron; S, sustentacular; Cc, ciliated columnar cells; Mc, 
mucous cells  
 
  38 7  Aims of the Thesis 
In this thesis CYP3A and some ABC-transport proteins have been examined 
in horse tissues that are sites of exposure of drugs and other xenobiotics. 
 
The specific aims of the thesis were: 
 
   To examine the gene and protein expression, catalytic activity and 
cellular localization of CYP3A in the intestines and liver in horse. 
 
   To investigate the gene and protein expression and CYP3A-related 
catalytic activity of the upper airways in horse.  
 
   To explore the gene and protein expression and cellular localization of P-
gp, BCRP, MRP1 and MRP2 in the intestines, liver and kidney in 
horse. 
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  40 8  Materials and Methods 
Below is a general description of the materials and methods used in this 
thesis. Detailed information on these matters is available in each paper. 
8.1  Animals and sample collections 
The tissues samples of the horses included in this thesis were collected at a 
slaughterhouse located in Huddunge, Sweden. All horses were standard bred 
trotters. Since this slaughterhouse has optimal conditions for samples 
preparation it was possible to collect the tissues immediately after slaughter. 
Tissues were taken from various parts of the intestines as shown in Table 9.  
Table 9. Sampling sites along the intestines in the horses included in the studies 
Tissues Position 
Duodenum (D1)  Immediately posterior to the pyloric sphincter (Pars prima duodeni) 
Duodenum (D2)  0.5 m posterior to the pyloric sphincter (Pars secunda duodeni) 
Duodenum (D3)  1 m posterior to the pyloric sphincter (Pars tertia duodeni) 
Jejunum (J1)  2.5 m posterior to the pyloric sphincter 
Jejunum (J2)  5.5 m posterior to the pyloric sphincter 
Jejunum (J3)  8.5 m posterior to the pyloric sphincter 
Jejunum (J4)  13.5 m posterior to the pyloric sphincter 
Ileum (I)  Immediately anterior to the ileo-cecal orifice 
Caecum (Ca)  Mid-part of the parietal surface of the corpus caeci 
Colon (C)  Origin of the small colon, posterior to the right dorsal colon 
 
Tissue samples were also taken from the liver, the kidney, the nasal olfactory 
and respiratory mucosa and the tracheal mucosa. The horses were 3-9 years 
old and were either mares or geldings. All horses passed the health control 
required for animals, which are intended for meat production. 
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activity 
In the intestines about 20 cm long segments were scraped smoothly with a 
scalpel at the indicated sampling sites. To evaluate our scraping we have 
studied tissue samples of the small intestine in a microscope before and after 
the scraping. It was concluded that the scraping included the enterocytes 
from the top of the villi down to the crypts and that only few cells from the 
lamina propria or submucosa layer were included. Samples of the nasal 
olfactory mucosa, the nasal respiratory mucosa and the tracheal mucosa were 
also obtained by smooth scraping of the epithelial surfaces. Liver samples 
were taken from the middle (central) lobe and kidney samples from the 
cortex.  
 
For preparations of microsomes the samples were homogenized in 0.05 M 
Tris-HCl buffer, pH 7.4 with 0.15 M KCl. As concerns preparation of 
intestinal microsomes complete trypsin inhibitor was also added. The 
homogenates were sedimented first at 10 000g and then twice at 105 000g. 
Microsomes were resuspended in the same buffer and stored at –78 ºC until 
used.  
 
Total CYP and cytochrome b5 contents were determined spectro-
photometrically according to the methods of Omura and Sato (1964) and 
Rutten et al. (1987). (Omura and Sato, 1964) and (Rutten et al., 1987). 
 
The NADPH P450 reductase activity was measure using cytochrome c as 
electron acceptor. We adapted the Cytochrome c Reductase (NADPH) 
Assay Kit from Sigma for usage in a 96-well microplate reader. An 
advantage of the 96-well plate adaptation is that less microsome are needed. 
This applications also implies time saving.  
 
CYP3A activity was assayed using the CYP3A selective fluorescent probe 3-
(3,4-difluorobenzyloxy)-5,5-dimethyl-4-(4-methylsulfonyl- phenyl)-5H-
furan-2-one (DFB). We used the protocol from Chayret et al. (1999) and 
adopted it for the microplate reader. In this assay DFB is metabolized to the 
fluorescent metabolite DFH. Studies with human liver microsomes have 
shown that the formation of DFH from DFB shows a high selectively for 
CYP3A4, which is the orthologue to horse CYP3A89. Human CYP3A5 
had low ability to form DFH from DFB, whereas other CYP-isoenzymes, 
such as CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1, 
CYP2C8, CYP2C9 and CYP2C19 were found to have very low or 
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setup of our studies assays with human liver microsomes were run in parallel 
with horse liver microsomes.  
8.3  Gene expression 
8.3.1  RNA preparation 
Tissue samples of the intestines and the liver were obtained from the horses 
as described under 7.2. Kidney samples were taken from the renal cortex. In 
paper I-IV total RNA was prepared with TRIzol. In paper V total RNA 
was prepared using Nucleospin RNA kit. The advantages of the latter 
method are that less tissue are needed, and that the method is less time 
consuming and easy to standardize. For both methods the RNA-purity and 
approximate concentration were determined spectrophotometrically by 
measuring the absorbance at 260 and 280 nm. Only samples with 260/280 
nm ratio exceeding 1.8 were selected. To check the integrity of the RNA 
the samples were run on an ethidium bromide-stained 1% agarose gel 
containing 18% formaldehyde. The RNA samples were stored at –78°C 
before use. 
8.3.2  Primer design 
In paper I-IV primers for CYP3A and P-gp were designed based on 
conserved regions in human, rat, pig, dog and cattle. In 2007 the horse 
genome was fully sequenced and available at several non-commercial 
databases. In paper V primers for BCRP, MRP1 and MRP2 were designed 
based on the horse sequences. Primers were picked to span at least two 
introns. An advantage of this kind of primer design is the possibility to check 
for genomic contamination. An amplified product from cDNA (no introns) 
will be smaller than those amplified from genomic DNA (containing 
introns). The specificity and size of the primers were checked on an agarose 
gel and the PCR-products were purified and sequenced.  
8.3.3  Real-Time RT-PCR 
Prior to the Real-Time RT-PCR analyses samples were normalized to the 
exact amount of RNA using Ribogreen assay. The real-time RT-PCR 
reaction was carried out using the Rotor-Gene 3000 and the RT-PCR Kit 
One step QuantiTect
TMSYBR
® Green from Qiagen. In paper I-IV relative 
quantification was used with a standard curve of known concentrations of 
the PCR-product. In paper V relative quantifications with the comparative 
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normalized to the housekeeping gene glyceraldehyde-3-
phosphatedehydrogenase (GADPH). The relative quantification with 
standard curve was chosen in paper I-IV since the horse genome was not 
sequenced at time of these studies and no known sequences of housekeeping 
genes were available. (Livak and Schmittgen, 2001) 
8.4  Protein expression and localization 
 
Antibodies with known epitope binding sequences are preferable and chosen 
if available. If the epitope binding sequence was not known antibodies with 
large species specificity were chosen (Table 10).  
  Table 10. Antibodies used in this thesis 
Name of 
antibodies 
Protein Species Epitope-binding 
sequence 
CYP3A4 CYP3A4  rat  anti-
human 
unknown 
C494 P-gp  mouse  anti- 
human 
internal epitope: 
Human PNTLEGN 
Horse   PNTLEGN 
C219 P-gp  mouse  anti- 
human 
internal epitope: 
Human VQEALD 
Horse   VQEALD 
JSB-1 P-gp  mouse  anti- 
human 
internal epitope:  
sequence unkown 
BXP-21   BCRP  mouse anti- 
human 
internal epitope:  
sequence unknown 
M2 III-6  MRP2  mouse anti- 
human 
internal epitope: 
 sequence unknown 
MRPm6   MRP1  mouse anti- 
human 
internal epitope: 
Human PSDLLQQRGL
a 
Horse   PSDLLQQKGL
a 
a the red amino acids showing the differences between horse and human in  
the epitope-binding sequence of MRPm6. 
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Protein expression was analyzed with Western Blot. CYP3A protein 
expression was studied using microsomal fractions. For P-gp, BCRP, MRP1 
and MRP2 protein expression was studied using membrane fractions. 
Protein samples were diluted in Laemmli loading buffer containing β-
mercapto ethanol. The proteins were separated on a 10% SDS-PAGE and 
transferred to nitrocellulose membranes. The membranes were stained with 
Ponceau S to verify an even transfer of the proteins. In paper II, IV, V the 
proteins were visualized with the Western Blotting Detection Reagent ECL 
(plus or advance) and analyzed in a ChemiDoc Quantification System with 
Quantity-One software. In paper III proteins were visualized with the 
Western Blotting Detection Reagent ECL plus and detected on film.  
 
 
8.4.2  Immunohistochemistry 
To study the cellular localization of the proteins immunohistochemistry was 
preformed. Samples for immunohistochemistry (1-2 mm thick and 3-6 mm 
long) of the various parts of intestines and liver were fixed in 4% 
paraformaldehyde (4°C). To remove intestinal contents the intestinal 
segments were washed carefully in NaCl-solution before the fixation. In 
paper IV and V samples from the kidney and liver were fixed in 
paraformaldehyde supplemented with mercury chloride to improve epitope 
binding of the antibodies. In negative controls the primary antibody was 
omitted.  
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9.1  Paper I  “CYP3A in horse intestines” 
The CYP3A gene expression in the intestines was high in the duodenum 
and jejunum and then declined rapidly in ileum, caecum and colon (Figure 
9A). In the liver the CYP3A expression was about 3-5 times lower than in 
the anterior part of the duodenum.  
 
Figure 9. Gene expression (A) and metabolic activity (B) of CYP3A in the different intestinal 
segments and the liver. Legends: see Table 9. 
The CYP3A-related metabolic activity showed a somewhat different pattern 
(Figure 9B). Thus, the CYP3A-related metabolic activity occurred at rather 
even level throughout the small intestine. Lower levels of metabolic activity 
were observed in the caecum and colon. In the liver the CYP3A-related 
metabolic activity was about equal of that in the small intestine.  
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enterocytes (Figure 10A and B). The immunostaining was most intense in 
the duodenum and the proximal parts of the jejunum. In the small intestine 
there was a more intense staining in the enterocytes of the tips of villi than 
in the enterocytes of the crypts.  In the large intestine a similar pattern was 
seen with a more intense staining in the surface enterocytes than the 
enterocytes in the crypts. Within the enterocytes the strongest staining was 
localized in the apical parts of the cytoplasm. In the liver the 
immunostaining of CYP3A was highest in the centrilobular hepatocytes 
(Figure 10C).  
 
 
Figure 10.  Immunohistochemistry of CYP3A in duodenum (A, B) and the liver (C). c, 
cytoplasm; e, enterocyte; cv, central vein; g, goblet cell; lp, lamina propria; n, nucleus. 
9.2  Paper II “Characterization of CYP3A-related metabolism in 
horse intestines and liver” 
The protein expression of CYP3A was highest in the duodenum and then 
decreased towards in the ileum, caecum and colon (Figure 11A). In the 
different parts of the intestinal tract there was a strong correlation between 
the CYP3A protein expression and the CYP3A mRNA expression (Figure 
11B). This also applied to the liver (Figure 11C).  
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Figure 11. (A) CYP3A protein expression in the intestines and liver. Correlations between 
expression of the CYP3A gene and protein in the intestines (B) and in the liver (C). 
Fairly low inter-individual variations were observed among the horses 
included in the study both concerning the CYP3A gene expression and the 
CYP3A metabolic activity. The gene expression and the metabolic activity 
of CYP3A in the duodenum correlated with these parameters in the 
jejunum and ileum, but not in the caecum or colon (Table 11).  
 
Table 11. Correlations between CYP3A mRNA expression in the duodenum and in the 
other intestinal segments and between CYP3A-related metabolic activity in the duodenum 
and in other intestinal segments 
Tissues 
 
CYP3A mRNA 
expression  
CYP3A-related metabolic 
activity  
Duodenum vs. Jejunum  r = 0.85; p < 0.05  r = 0.90; p < 0.05 
Duodenum vs. Ileum  r = 0.94; p < 0.05  r = 0.87; p < 0.05 
Duodenum vs. Caecum  r = 0.64; N.S
a  r = 0.1; N.S
a 
Duodenum vs. Colon  r = 0.68; N.S
a  r = 0.3; N.S
a 
a N.S not significant 
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In addition, in the liver these parameters matched with those in the small 
intestines, but not in the caecum and colon (Table 12).  
 
Table 12. Correlations between CYP3A mRNA expression in the liver and in the different 
intestinal segments and between the CYP3A-related metabolic activity in the liver and in 
different intestinal segments 
Tissues 
 
CYP3A mRNA 
expression  
CYP3A-related metabolic activity  
Liver vs. Duodenum  r = 0.70; p < 0.05  r = 0.82; p < 0.05 
Liver vs. Jejunum  r = 0.78; p < 0.05  r = 0.91; p < 0.05 
Liver vs. Ileum  r = 0.78; p < 0.05  r = 0.86; p < 0.05 
Liver vs. Caecum  r = 0.25; N.S
a  r = 0.26; N.S
a 
Liver vs. Colon  r = 0.70; N.S
a  r = 0.66; N.S
a 
a N.S not significant 
 
The NADPH P450 reductase activity was slightly higher in the small 
intestines than in the large intestines. The amount of cytochrome b5 was 
somewhat higher in the ileum and caecum than the other intestinal 
segments. In the liver both the NADPH P450 reductase activity and the 
contents of cytochrome b5 were much higher than in the intestines. 
Estimation of the quotients for the NADPH P450 reductase activity and the 
cytochrome b5 content related to CYP3A gene expression showed the 
highest ratios in the caecum, colon and ileum (Table 13). 
Table 13. Quotients of NADPH P450 reductase activity versus CYP3A mRNA expression 
and cytochrome b5 contents versus CYP3A mRNA expression in the different intestinal 
segments and the liver 
Tissues  NADPH P450 reductase activity: 
CYP3A mRNA 
expression 
cytochrome b5 contents: 
CYP3A mRNA 
expression 
 
Duodenum 
 
1.4 
 
0.03 
Jejunum 7  0.1 
Ileum 111  4 
Caecum 611  64 
Colon 150  11 
Liver 25  0.6 
 
 
  50 9.3  Paper III “Cytochrome P450 3A, NADPH cytochrome P450 
reductase and cytochrome b5 in the upper airways in horse” 
 
The gene expression of CYP3A was much higher in the liver than in the 
tissues of the upper respiratory airways (Figure 12A). Among the latter 
tissues the highest expression of the CYP3A gene was found in the nasal 
olfactory mucosa. Lower levels of CYP3A gene expression were observed in 
the nasal respiratory and tracheal mucosa (Figure 12A). An analysis of 
protein expression demonstrated the same pattern with highest level of the 
CYP3A protein in the liver, lower levels in the nasal olfactory mucosa and 
the weakest levels in the nasal respiratory and tracheal mucosa (Figure 12B). 
The CYP3A-related metabolic activity showed another pattern with 
considerably higher activity in the tissues of the upper respiratory airways 
than the liver (Figure 12C).  
 
Figure 12. Gene expression of CYP3A (A), Western blot of CYP3A (B) and CY3A 
metabolic activity (C) in the tissues of the upper respiratory airways and the liver. As a 
control human recombinant CYP3A4 was run in parallel in the Western blot analysis. 
Legends; L, liver; R, nasal respiratory mucosa; O, nasal olfactory respiratory mucosa; Tr, 
tracheal mucosa; HCYP, human recombinant CYP3A4. 
It thus appears that the pattern of the CYP3A metabolic activity in the 
upper respiratory tract does not correlate with the CYP3A gene and protein 
expression. Determinations of NADPH P450 reductase activity and 
cytochrome b5 showed that the levels of these co-factors in the relation to 
the CYP3A gene and protein expression were much higher in the tissues of 
the upper respiratory airways than in the liver.  
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lymphocytes in horse” 
The highest MDR1 gene expression was found in the duodenum and the 
proximal parts of the jejunum. The gene expression then declined rapidly to 
low levels in ileum, caecum and colon (Figure 13). MDR1 gene expression 
was also observed in the liver and kidney with much higher levels in the 
liver than the kidney. Peripheral blood lymphocytes also showed MDR1 
gene expression. The Western blot showed presence of P-gp protein in the 
intestines, liver, kidney and peripheral blood lymphocytes. There was no 
statistically significant correlation between the MDR1 gene expression and 
the P-gp protein levels in the various intestinal segments. 
 
Figure 13. MDR1 gene expression of the intetines, the liver and the kidney. The gene 
expression in D3 and J1 was statistically different from the other intestinal segments (marked 
with *). Legends: see Table 9. 
Immunohistochemistry showed localization of P-gp in the microvilli of the 
apical surface membranes of the enterocytes throughout the intestinal tract, 
the most intense staining being present in the proximal parts of the intestines 
(Figure 14A). The enterocytes of the villi in the small intestines showed a 
more intense staining than in the crypts. Immunostaining of P-gp was also 
observed in the intraepithelial and lamina propria lymphocytes as well as in 
lymphocytes in the blood vessels (Figure 14A). The number of 
intraepithelial lymphocytes was higher in the duodenum and the jejunum 
than in the distal parts of the intestines. In the liver P-gp was localised in the 
bile canalicular membranes of hepatocytes (Figure 14B). In the kidney the 
P-gp was localized in the luminal and basolateral surface of cells in the 
proximal tubules and in the luminal surfaces of the cells in the loops of 
Henle and the cells of the distal tubules. There was a weak staining in the 
mesangial cells of the glomeruli (Figure 14C).  
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Figure 14. Immunohistochemistry of P-gp. (A) P-gp immunostaining is present in the apical 
membranes of the enterocytes and cell membranes of intraepithelial lymphocytes in the 
duodenum. (B) P-gp immunostaining in bile canalicular membranes of hepatocytes. (C) P-gp 
immunostaining in the proximal and distal tubules and the loop of Henle in the kidney. 
Legends; g, goblet cell; iel, intraepithelial lymphocytes; dt, distal tubule; pt, proximal tubule; 
h, loops of Henle. 
Sequence alignment showed that P-gp in horse (XP_001592073) has a 99 
amino acid long insertion about 20 amino acids from the N-terminal part of 
the protein, which is not present in the other examined species. Another 
shorter insertion (6 amino acids) is present at the amino acid positions 140-
145 from the N-terminal of horse P-gp, but not in the other examined 
species (Figure 15). 
 
Figure 15. Kyte-Doolittle hydropathy plots of the N-terminal regions of horse and human P-
gp. The plots were drawn with a window of 19. The amino acid number is given on the 
horizontal axes; the hydropathy score is given on the vertical axes. Hydrophobic 
transmembrane regions have scores from about 1.8 (indicated by a red line). The location of 
the 99 amino acid insertion in horse P-gp is indicated by a dotted line. An arrow indicates 
the location of the 6 amino acid insertions in horse P-gp. The green arrows indicate the 
conserved regions of P-gp starting from amino acid 146 in horse P-gp and 41 in human P-
gp. 
  53 9.5  Paper V “Expression and localization of BCRP, MRP1 and 
MRP2 in intestines, liver and kidney in horse” 
 
The results showed a prominent gene expression of BCRP and MRP2 in 
the small intestines and liver. In contrast to BCRP the gene expression of 
MRP2 was low in the caecum and colon (Figure 16). In the kidney both 
these transporters showed a rather low expression. In all tissues the gene 
expression of MRP1 was lower than for BCRP and MRP2. The pattern of 
the intestinal MRP1 gene expression showed a slow increase from the 
duodenum to the caecum and colon (Figure 16).  
 
Figure 16. Gene expression of BCRP, MRP2 and MRP1 in the different intestinal segments, 
liver and kidney. Legends: see Table 9. 
 
For MRP1 and MRP2 there was a statistically significant correlation 
between the protein and gene expression, but no such correlation was 
observed for BCRP. 
 
Immunohistochemistry showed localization of BCRP and MRP2 at the 
apical surfaces of the enterocytes in the small intestine with a stronger 
immunostaining of the cells at the tips of the intestinal villi than of the cells 
in the intestinal crypts (Figure 17A and B). In the large intestine there was a 
lack of immunostaining for MRP2, whereas BCRP showed a weak staining 
of the apical cellular membranes in the caecum. In addition, both in the 
small and large intestine BCRP immunoreactivity was observed in the cells 
residing in the intestinal lamina propria, which mainly consist of 
lymphocytes and in addition macrophages and mast cells. For MRP1 the 
enterocytes of the large intestine showed a marked granular immunostaining 
(Figure 17C).  
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Figure 17. Immunostaining of BCRP (A) and MRP2 (B) in the enterocytes of the small 
intestine and of MRP1 (C) in the enterocytes of the caecum. 
In Brunner’s glands, which are present in the submucosa of the duodenum 
and proximal jejunum, a marked immunostaining for BCRP and MRP1 
was observed in serous acini, but not in mucous acini (Figure 18A and B).  
 
Figure 18.  Immunostaining of BCRP (A) and MRP1 (B) in the cells of serous acini of 
Brunner’s glands.  
In the liver immunostaining of MRP2 was present in the bile canalicular 
membranes of the hepatocytes (Figure 19A). BCRP showed immuno-
reactivity in the cytoplasm of hepatocytes present in the peripheral parts of 
the liver lobuli, in cell membranes of interlobular bile ducts and in the 
endothelium of interlobular veins and arterioles (Figure 19B). No specific 
hepatic immunostaining was observed for MRP1. 
 
Figure19. Immunostaining of MRP2 in the bile canalicular membranes of hepatocytes (A) 
and of BCRP in the peripheral parts of the lobuli in the liver (B). 
 
  55 In the kidney BCRP and MRP2 showed a marked immunostaining in the 
luminal and basolateral membranes of the cells of the loop of Henle and the 
cells of the distal tubules and the collecting ducts (Figure 20A and B). No 
specific renal immunostaining was observed for MRP1.  
 
Figure 20. Immunostaining of BCRP (A) and MRP2 (B) in the kidney. Legends; pt, 
proximal tubule; dt, distal tubule; h, loop of Henle. 
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The disposition of drugs in horses is sometimes difficult to foresee because of 
factors that contribute the fate of equine xenobiotics have not been well 
characterized. It has for example been shown that the oral absorption of 
some antimicrobials and antihistamines is lower in the horse compared to 
other animals (Davis et al., 2005; Olsén et al., 2007; Törneke et al., 2003). It 
is therefore a need to obtain additional information on the conditions that 
determine uptake, metabolism and excretion of drug is horses. The 
localization and expression of CYP3A and the transport proteins P-gp, 
BCRP, MRP1 and MRP2 have not previously been examined in tissues of 
horse.  
10.1 CYP3A 
10.1.1  CYP3A in the intestines and the liver  
The results of the present thesis have shown that the gene and protein of 
CYP3A are highly expressed in the proximal intestines with a decreasing 
gradient towards the distal parts of the intestines. The immunohisto-
chemistry showed CYP3A localization in the enterocytes, with a similar 
gradient from the proximal to the distal parts of the intestines. Similar 
patterns of CYP3A gene and protein expression and CYP3A immuno-
staining have been shown in man, dog and trout (Kaminsky and Zhang, 
2003; Kyokawa et al., 2001; Lee et al., 2001). 
 
The results showed relatively high levels of CYP3A-related metabolic 
activity in the ileum, caecum and colon in spite of low gene and protein 
expression in these parts of the intestines. It is known that NADPH P450 
reductase is a necessary component in the CYP monooxygenase cycle and 
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enzymes by supplying electrons to the CYP cycle (Nakajima et al., 2002). In 
addition cytochrome b5 is known to enhance the metabolic activity of CYP 
enzymes by facilitating the electron transfer to the CYP cycle (Schenkman 
and Jansson, 2003). Our results showed that the levels of these cofactors in 
the relation to the CYP3A gene and protein expression were higher in the 
distal than the proximal parts of the intestines. These data indicate that an 
efficient electron transfer from the NADPH reductase and cytochrome b5 to 
CYP3A in the ileum, caecum and colon may explain the marked CYP3A-
related metabolic activity in these intestinal segments. 
 
The inter-individual variations in CYP3A mRNA expression and in 
CYP3A-related metabolic activity in the intestines and the liver were fairly 
low among the horses included in our study. However, in man large inter-
individual variations both as concern CYP3A mRNA expression and 
CYP3A-related metabolic activity have been shown in the liver and the 
intestines (Paine et al., 1997; Rodriguez-Antona et al., 2001; Watanabe et 
al., 2004). The expression of CYP-enzymes is dependent on various factors, 
such as genetical, environmental, pathological, hormonal and dietary 
conditions. The horses included in our study are of the same breed and of 
similar age and they have been kept in a comparable environment and given 
similar feed. This implies that the factors affecting CYP3A expression and 
metabolic activity in these horses may vary to a lesser extent than in man, 
which in turn can result in low variation in these parameters. However, 
herb supplements in the horse diet may affect CYP enzymes and ABC-
transport proteins activity and possibly cause herb-drug interactions.  
 
Our results showed that the gene expression and protein expression of 
CYP3A correlated both in the intestines and in the liver. These data indicate 
that the regulation of CYP3A protein expression in these tissues mainly 
occurs at a pre-translational level. These results are consistent with results 
reported for CYP3A4 in human intestines and liver (Berggren et al., 2007; 
Watanabe et al., 2004). The CYP3A gene and protein expression in the 
liver correlated with the CYP3A-related metabolic activity in the liver. 
Studies in man have shown that in the liver there is a correlation between 
CYP3A mRNA and protein expression and CYP3A-related metabolic 
activity (Paine et al., 1997; Rodriguez-Antona et al., 2001; Watanabe et al., 
2004). 
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in the duodenum, jejunum and ileum were in addition found to match with 
these parameters in the liver. In contrast, no significant correlations were 
observed when the CYP3A mRNA expression or the CYP3A metabolic 
activity in the caecum and colon were matched with these parameters in the 
liver. We also found that matching of the CYP3A mRNA expression and 
the CYP3A-related metabolic activity in the duodenum with these 
parameters in the other intestinal segments gave a statistically significant 
correlation for the jejunum and ileum, but not for the caecum and colon. 
The information obtained concerning the inter-individual variations in 
CYP3A gene expression and metabolic activity among the horses in the 
study support the conclusion that CYP3A in the liver is co-regulated with 
CYP3A in the small intestines, but not in the large intestines. A possible 
explanation for these observations is that inducers or inhibitors of CYP3A, 
which can be present in the feed of the horses, during absorption and 
metabolism concomitantly, will influence CYP3A both in the liver and in 
the small intestines. This phenomen will not occur in the caecum or colon, 
which mainly is engaged in microbial breakdown of fibrous feed 
components. Our results indicate that it may be possible to analyse CYP3A 
mRNA in duodenal pinch biopsies to estimate CYP3A-related metabolic 
activity in the jejunum, ileum and liver. 
 
10.1.2  CYP3A in the upper respiratory airways 
Our results showed that the CYP3A related catalytic activity in the tissues of 
the upper airways was considerably higher than in the liver. The CYP3A 
gene and protein expression, on the other hand, were found to be much 
higher in the liver than in the other tissues. It thus appears that the pattern of 
CYP3A metabolic activity does not correlate with the CYP3A gene and 
protein expression. A possible explanation for this is that NADPH P450 
reductase and cytochrome b5, which were found to be present in relatively 
high levels in the upper airways, may facilitate the electron transfer into the 
CYP-cycle in the cells in these tissues. Studies in several other species, such 
as cattle, sheep, swine, hamster, rat and mouse, have shown high CYP-
dependent bioactivation of various xenobiotics in the upper airways (Larsson 
et al., 1989; Marini et al., 1998; Reed, 1993; Reed et al., 1986; Tjälve, 
1991; Tydén et al., 2004b). As concern hamster and cattle both the activity 
of NADPH P450 reductase and the amount of cytochrome b5 in relation to 
the CYP content have been reported to be higher in these extrahepatic 
tissues than in the liver (Larsson et al., 1989; Reed et al., 1986). 
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10.2.1   Protein sequence analysis 
The ABC-transport proteins have been highly conserved during the 
evolution (Higgins, 1992). Protein sequence alignments of horse P-gp, 
BCRP, MRP1 and MRP2 showed high identity with corresponding 
orthologues in human, dog and rat.  
 
Interestingly, two amino acid insertions, one containing 99 amino acids, the 
other 6 amino acids, were found to be present in the N-terminal of horse P-
gp, but not in some other examined species. A Kyte-Doolittle 
hydrophobicity plot showed that the insertions are hydrophobic and 
probably located intracellularily. Further studies to explore the possible 
function of these insertions would be of interest.  
10.2.2  P-gp, BCRP, MRP1 and MRP2 in the intestines 
The studies demonstrate gene and protein expression of P-gp, BCRP, 
MRP1 and MRP2 along the intestinal tract in horse. It appeared that in all 
tissues the expression of MRP1 was lower than for P-gp, BCRP and 
MRP2. This observation correlates with previous reports in other species 
(Cherrington et al., 2002; Conrad et al., 2001; Hilgendorf et al., 2007; 
Langmann et al., 2003; MacLean et al., 2008; Nishimura and Naito, 2005; 
Peng et al., 1999). 
 
The patterns of the distribution of the transporters along the intestinal tract, 
with a decreasing level of P-gp from the small intestines towards the caecum 
and colon, with low level of MRP2 in the caecum and colon, slowly rising 
levels of MRP1 from the duodenum to the caecum and colon and 
considerable variations of the expression of BCRP in the different intestinal 
segments, also correlate with reports in other species (Berggren et al., 2007; 
Conrad et al., 2001; MacLean et al., 2008). The gene and protein expression 
in the intestines showed a significant correlation for MRP1 and MRP2, but 
not for P-gp or BCRP. These data indicate that the expression of MRP1- 
and MRP2-proteins in horse intestines is regulated at a transcriptional level. 
The absence of such correlation for P-gp and BCRP indicates that 
posttranscriptional factors are involved in the expression of these proteins.  
 
The immunohistochemistry showed localization of P-gp, BCRP and MRP2 
in the apical cell membranes of enterocytes in the duodenum, jejunum and 
ileum. In the large intestines there was a weaker immuno-staining for P-gp 
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patterns of intestinal localization of P-gp, BCRP and MRP2 have been 
observed in man and rodents (Fetsch et al., 2006; Flens et al., 1996; Peng et 
al., 1999). P-gp and BCRP in the enterocytes are assumed to limit the oral 
absorption of xenobiotics by pumping compounds back into the intestinal 
lumen. MRP2 is supposed to act as an out-transporter of intracellularly 
formed conjugates. In the large intestines the enterocytes can be presumed 
to be exposed to low levels of xenobiotics, which as a result would require 
low level of the transporters. CYP- and transferase-enzymes in the 
enterocytes, which are present in higher levels in the small than in the large 
intestines (Kaminsky and Zhang, 2003; Paine et al., 1997; Tydén et al., 
2004a) may act in concert with the transporters to limit xenobiotic 
absorption. 
 
MRP1 showed a cytoplasmic granular staining in enterocytes of the caecum 
and colon. A cytoplasmic localization of MRP1 in the enterocytes in various 
parts of the intestines in human has been reported by (Flens et al., 1996). 
Although the function of MRP1 is not fully understood, it has been 
assumed that it acts as an exporter of xenobiotic conjugates from cells in 
several tissues. It has been suggested that the role of MRP1 may be to 
protect the cells containing this transporter rather than the whole organism 
(Berggren et al., 2007). 
 
In addition to presence of P-gp and BCRP in the apical membranes of the 
enterocytes our results indicated that these transporters are present in 
intestinal lymphocytes and macrophages. It is has been shown that P-gp and 
BCRP in man is expressed in lymphocytes and monocytes in the blood 
(Moon et al., 2007). It has been proposed that P-gp and BCRP in the blood 
mononuclear cells may be involved in membrane transport of leukotriene 
C4, platlet activating factor and some cytokines (Farrell et al., 2000; Moon 
et al., 2007; Tsujimura et al., 2005). In addtion the transporters present in 
these cells may restrict drug access to these important sites of action. 
 
BCRP and MRP1 were found in the cells of the serous acini of Brunner’s 
glands of the horse. This species is one of few mammals in which Brunner’s 
glands are comprised of both mucous and serous tubular acini (Pfeiffer and 
Dabareiner, 1992). It can be noted that BCRP and MRP1 have been found 
in serous glands at other sites, such as in salivary glands, some glands in the 
respiratory pathways and pancreas (Fetsch et al., 2006; Flens et al., 1996; 
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at present.  
 
10.2.3  P-gp, BCRP, MRP1 and MRP2 in the liver 
In the liver much higher levels of gene and protein expression were 
observed for P-gp, BCRP and MRP2 than for MRP1. The 
immunohistochemistry of P-gp and MRP2 showed localization in the bile 
canalicular membranes of hepatocytes. This localization has been found in 
other mammals (Kool et al., 1997; Li et al., 2003; Thiebaut et al., 1987). P-
gp and MRP2 at these sites are considered to be involved in the extrusion of 
some drugs and other xenobiotics from the hepatocytes in to the bile (Faber 
et al., 2003). MRP2 is also active in the elimination of bilirubin from 
hepatocyte into bile (Schinkel and Jonker, 2003). 
 
BCRP showed a granular cytoplasmic staining in the hepatocytes in the 
peripheral parts of the liver lobuli and in addition a staining of the cell 
membranes of interlobular bile ducts and the endothelium of interlobular 
veins and arterioles. In contrast, studies in man and mouse have shown 
localization of BCRP in the bile canalicular membranes of hepatocytes 
(Vander Borght et al., 2006). In addition, in man immunostaining of BCRP 
was reported in the bile ducts and the endothelium of the blood vessels 
(Vander Borght et al., 2006). In normal livers of rats the hepatocytes have 
been reported to lack BCRP-immunostaining, whereas bile ducts and 
vessels were stained (Vander Borght et al., 2006). It appears that there can be 
large species differences in the hepatic localization of BCRP between 
species.  
 
It has been shown that in human liver disease cytoplasmic expression of 
BCRP is present in hepatic progenitor cells, which are localized in the 
periphery of liver lobuli, and it was proposed that BCRP in these cells may 
contribute to resistance to cytotoxic agents and xenotoxins (Vander Borght 
et al., 2006). It is not known at present whether the BCRP immunopositive 
cell in horse also include the progenitor cells. However, BCRP, which is 
present in the peripheral parts of the liver lobuli in horse, may also act to 
protect the hepatocytes at these sites from potentially toxic xenobiotics. 
 
The protein expression of MRP1 was higher in the liver than in the kidney 
in horse. This correlates with observations in (Flens et al., 1996). In contrast, 
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than in the liver (Conrad et al., 2001). 
 
It appears that there can be large differences in the hepatic localization and 
expression of the ABC-tarnsporters between species. The impact which 
these species differences may have on metabolism and elimination of drugs is 
not known as yet. 
 
10.2.4  P-gp, BCRP, MRP1 and MRP2 in the kidney 
As in the intestines and liver the levels of gene and protein expression of P-
gp, BCRP and MRP2 in the kidney were much higher than for MRP1. 
For all the transport proteins the gene and protein expression were lower in 
the kidney than in the liver. As mentioned in dog the expression level of 
MRP1 is higher in the kidney than in the liver (Conrad et al., 2001). 
  
P-gp, BCRP and MRP2 were localized both in the apical and basolateral 
membranes of cells in Henles loop and in the cells of the distal tubules and 
collecting ducts P-gp was also present in the luminal membranes of the cells 
of the proximal tubules. The role of P-gp and BCRP in the kidney in horse 
may be to participate in active tubular excretion of xenobiotics reaching the 
kidneys via the blood, pumping of xenobiotics absorbed from the urine back 
into the tubular lumen as well as transport of compounds from tubular cells 
into the blood. Similar functions may be assumed for MRP2, although the 
substrates for this transporter can be presumed to mainly involve conjugates 
of drug and other xenobiotic. P-gp, BCRP and MRP2 have been reported 
to be present solely in the apical membranes of the cells in the proximal 
tubules in man and rodents (Huls et al., 2008; Schaub et al., 1997). It is 
important to recognize that the differential renal patterns of the tissue 
expression of the transporters also imply that variations in the functions of 
these transporters in the kidneys can vary between species. 
 
Paper IV and V highlights that marked species differences may exist between 
horse and other species as concern gene and protein expression and cellular 
localization of the transporters in the tissues. This indicates that the effects of 
the transporters on the kinetics and dynamics of drugs may vary between 
horse and other species. Further studies aiming at exploring these issues 
would be of great interest. 
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  64 11 Conclusions 
Some salient results, which have emerged in this thesis, are: 
 
   The CYP3A gene and protein expression are high in the small intestines 
of horse. The gene expression of CYP3A in the first part of duodenum 
was even higher than in the liver. 
 
   There are correlations between CYP3A gene and protein expression 
both in the intestines and the liver, indicating transcriptional regulation 
of CYP3A protein expression in these tissues in horse. 
 
   The CYP3A gene expression and the CYP3A-related metabolic activity 
in the duodenum, jejunum and ileum were found to match with these 
parameters in the liver. This observation may have clinical relevance, 
since it may be possible to analyze the CYP3A expression in duodenal 
pinch biopsies and predict CYP3A-related metabolic activity in the liver 
in horse. 
 
   In contrast to the correlation described above between CYP3A gene 
expression and the CYP3A-related metabolic activity in the small 
intestines and liver, no such correlation was observed when these 
parameters were matched with those in the caecum and colon. It is 
possible that inducers or inhibitors of CYP3A, which can be present in 
the feed of horse, concomitantly will influence CYP3A both in the small 
intestines and in the liver. This may not occur in the caecum and colon, 
which mainly are engaged in microbial breakdown of fibrous feed 
components. 
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the upper airways in spite of low levels of gene and protein expression of 
CYP3A in these tissues. A possible explanation for this observation is that 
the CYP3A-related metabolic activity in the upper airways will be 
facilitated by an efficient electron transfer into the CYP-cycle due to 
presence of high levels of NADPH P450 reductase and cytochrome b5 in 
these tissues. 
 
   CYP3A gene expression and CYP3A-related metabolic activity in the 
intestines and the liver showed rather low inter-individual variations 
among the horses included in the study. This implies that environmental 
and other factors, which may affect CYP3A expression and metabolic 
activity, may vary to a lesser extent than in man, in whom higher 
variations in these parameters have been observed. 
 
   The amino acid sequences of the proteins of the ABC-transporter family 
are generally highly conserved between species. However, protein 
sequence alignment showed that in horse P-gp has two amino acid 
sequences, respectively 99 and 20 amino acids long, inserted at the N-
terminal region of the protein, which were absent in the other species 
examined. The possible function of these insertions is not known at 
present. Protein sequence alignment of BCRP, MRP1 and MRP2 
showed that these proteins are highly conserved between horses and 
other species. 
 
   In horse gene and protein expression of P-gp, BCRP, MRP1 and 
MRP2 were found in the intestines as well as in the liver and kidney. 
The expression and the localization of the transporters in these issues of 
horse showed both similarities and differences compared to other species. 
 
   Immunohistochemistry showed localization of P-gp, BCRP and MRP2 
in the apical cell membranes of the enterocytes in the small intestines, in 
which these transport proteins may play a role in the regulation of oral 
bioavailability of some xenobiotics by pumping compounds from the 
inside of the enterocytes back into lumen of the intestines. Additional 
observations were that P-gp and BCRP are present in intraepithelial and 
lamina propria intestinal lymphocytes and that BCRP and MRP1 are 
present in the cells of serous acini of Brunner’s glands. 
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membranes, in which they may act to excrete drugs and other 
xenobiotics from the hepatocytes into the bile. BCRP was localized in 
the cytoplasm of cells in the peripheral parts of the liver lobuli. The role 
of this transporter in these cells is not known at present. 
 
   In the kidney the transporters were found in different parts of the 
nephrons, in which they may function to promote tubular secretion of 
xenobiotics into urine or transport of xenobiotics xenobiotics from the 
tubular cells into the blood. 
 
   Collectively the results of the present thesis indicate that CYP3A and the 
examined ABC-transport proteins have important roles for bioavailability 
and elimination of substrate compounds in horse. 
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  68 12 Future Research 
The results of this thesis indicate that CYP-enzymes and transport proteins 
are of great importance for the disposition of drugs and other xenobiotics in 
horse. Further studies aiming at exploring the roles of CYP-enzymes and 
transport proteins for the fate of xenobiotics in horse as well as in other 
domestic animals would be of interest. A few examples are given below. 
 
   The CYP-enzymes involved in the metabolism of xenobiotics belong to 
the CYP-families 1 2 and 3. It would be of interest to explore the 
occurrence of some CYP-enzymes in these families (e.g. CYP1A, 
CYP2C, CYP2D and CYP2E) in the intestines and liver in horse. 
Studies on the occurrence of these enzymes in the upper respiratory 
airways of horse would also be of interest. 
 
   It would be of interest to examine the occurrence and metabolic 
activities of CYP-enzymes of the 1, 2 and 3 families in the intestines, 
liver and upper airways in other domestic animals. 
 
   It would be of interest to explore the occurrence of additional transport 
proteins in the tissues of horse, as well as in other domestic animals. 
 
   It would be of interest to map in detail the spectrum of drugs used in 
horse and other domestic animals that are substrate for different CYP-
enzymes and transport proteins. “Model drugs” may then be used in in 
vivo studies to explore the roles of the CYP-enzymes and the transporters 
for the disposition of drugs. 
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  82 13 Sammanfattning på svenska  
I avhandlingen har cytokrom P450 3A (CYP3A) och ABC-
transportproteinerna P-glykoprotein (P-gp), breast cancer resistance protein 
(BCRP), multidrug resistance protein 1 (MRP1) och multidrug resistance 
protein 2 (MRP2) studerats hos häst. CYP3A och transportproteinerna har 
stor betydelse för upptag, metabolism och utsöndring av läkemedel och 
andra främmande ämnen. Det finns många undersökningar där CYP3A och 
transportproteinerna har studerats hos gnagare och människa, medan 
däremot undersökningar hos häst saknas. 
 
I den första delen av avhandlingen (arbete I-III) studerades gen- och 
proteinuttryck och den metaboliska aktiviteten hos CYP3A i tarmarna, 
levern och de övre luftvägarna hos häst. I tarmen fanns det högsta gen- och 
proteinuttrycket i duodenum och jejunum. En intressant observation var att 
genuttrycket i den första delen av duodenum var ca. 4,5 gånger högre än i 
levern. Det fanns en korrelation mellan genuttrycket och proteinuttrycket 
för CYP3A både i tarmarna och i levern, vilket indikerar att det är en pre-
translationell reglering av proteinuttrycket för CYP3A i dessa vävnader hos 
häst. Genuttryck och metabolisk aktivitet för CYP3A i duodenum, jejunum 
och ileum korrelerade med dessa parametrar i levern. Denna observation kan 
ha klinisk relevans, eftersom det kan vara möjligt att analysera genuttrycket 
för CYP3A i biopsier från duodenum och på basis av detta avgöra den 
CYP3A-relaterade metabolismen i levern hos häst. 
 
Man vet att CYP-relaterad metabolisk aktivitet är beroende av närvaro av 
elektrondonerande enzymer såsom NADPH P450-reduktas och cytokrom 
b5. Våra resultat visade relativt höga nivåer av CYP3A-relaterad metabolism i 
de distala delarna av tarmkanalen och i de övre luftvägarna hos häst, trots 
låga nivåer av gen- och proteinuttryck i dessa vävnader. En möjlig förklaring 
  83 till dessa observationer är att den CYP3A-relaterade metaboliska aktiviteten i 
dessa delar av tarmen och i de övre luftvägarna stimuleras av en effektiv 
elektronöverföring till CYP3A från NADPH P450-reduktas och cytokrom 
b5, som återfanns i relativt höga halter i dessa vävnader.  
 
Den CYP3A-relaterade metaboliska aktiviteten i tarmarna och i levern 
visade relativt låga interindividuella variationer hos hästarna som ingick i 
undersökningen. Det kan vara så att genetiska faktorer, liksom miljöfaktorer, 
som kan påverka uttryck och metabolisk aktivitet hos CYP3A, varierar 
mindre hos de undersökta hästarna än hos människa, där större variationer 
har observerats för dessa parametrar. 
 
I den andra delen av avhandlingen (arbete IV-V) studerades gen- och 
proteinuttrycket och den cellulära lokalisationen av transportproteinerna P-
gp, BCRP, MRP1 och MRP2 i tarmar, lever och njurar hos häst. 
Aminosyrasekvenserna för dessa proteiner är i allmänhet högt konserverade 
mellan olika djurslag. Emellertid visade proteinsekvensjämförelser att det för 
P-gp hos häst finns två aminosyrasekvenser, som består av respektive 99 och 
6 aminosyror, i den N-terminala delen av proteinet som inte finns hos ett 
par andra undersökta djurslag eller hos människa. Den funktionella 
betydelsen av detta är ännu okänd. Proteinsekvensjämförelser för BCRP, 
MRP1 och MRP2 visade att dessa proteiner hos häst är mycket lika de hos 
ett par andra undersökta djurslag och hos människa.  
 
Höga nivåer av gen- och proteinuttryck för P-gp och MRP2 återfanns i 
duodenum, jejunum och ileum, medan däremot nivåerna i caecum och 
kolon var låga. Gen- och proteinuttrycket för BCRP varierade i olika 
tarmavsnitt. För MRP1 sågs ett långsamt ökande gen- och proteinuttryck 
från duodenum till kolon. För alla transportproteinerna var gen- och 
proteinuttrycket högre i levern än i njurarna. En annan observation var att 
gen- och proteinuttrycket för MRP1 var lägre i alla vävnader jämfört med 
de andra transportörerna. 
 
Immunohistokemi visade förekomst av P-gp, BCRP och MRP2 i de apikala 
cellmembranen i tarmens enterocyter. Dessa transportproteiner kan ha stor 
betydelse för regleringen av det orala upptaget av läkemedel och andra 
främmande ämnen genom pumpa substanser som tagits upp i cellerna 
tillbaka till tarmlumen. Ytterligare observationer var att P-gp och BCRP 
återfinns i de lymfocyter som finns i tarmslemhinnan och att BCRP och 
  84 MRP1 återfinns i serösa acini i Brunners körtlar i duodenum och början av 
jejunum.   
 
I levern återfanns P-gp och MRP2 i levercellernas gallkanalikuli, i vilka de 
kan verka vid utsöndringen av främmande ämnen i gallan. BCRP återfanns i 
cytoplasman i cellerna i de perifera delarna av leverlobuli. Det är möjligt att 
BCRP i dess celler kan ge skydd mot negativa effekter av hepatotoxiska 
substanser. 
 
I njurarna återfanns transporproteinerna i olika delar av nefronen. 
Funktioner av transportproteinerna i njuren kan vara att medverka i 
utsöndringen av främmande ämnen från blodet till urinen, pumpa tillbaka 
substanser som tagits upp i cellerna i nefronen till urinen, samt transportera 
ämnen från cellerna i nefronen ut i blodet. 
 
Sammantaget indikerar resultaten i avhandlingen att CYP3A och de 
undersökta ABC-transportproteinerna har stor betydelse för upptag, 
metabolism, vävnadsfördelning och utsöndring av läkemedel och andra 
främmande ämnen hos häst.  
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